Scarica l'app Stockscreener
152.69
3.86%
5.68
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$147.01
Aprire:
$150
Volume 24 ore:
1.82M
Relative Volume:
9.44
Capitalizzazione di mercato:
$2.95B
Reddito:
$152.42M
Utile/perdita netta:
$45.24M
Rapporto P/E:
60.83
EPS:
2.51
Flusso di cassa netto:
$6.97M
1 W Prestazione:
+12.98%
1M Prestazione:
+25.46%
6M Prestazione:
+37.08%
1 anno Prestazione:
+53.30%
Intervallo 1D:
$149.00
$156.53
Intervallo di 1 settimana:
$132.21
$156.53
Portata 52W:
$93.58
$156.53
Ligand Pharmaceuticals Inc Stock (LGND) Company Profile
Nome
Ligand Pharmaceuticals Inc
Settore
Industria
Telefono
858-550-7500
Indirizzo
3911 SORRENTO VALLEY BLVD, SAN DIEGO, CA
Confronta LGND con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LGND
Ligand Pharmaceuticals Inc
|
152.69 | 2.88B | 152.42M | 45.24M | 6.97M | 2.51 |
|
VRTX
Vertex Pharmaceuticals Inc
|
387.77 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
556.55 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
429.93 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
637.56 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.10 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
Ligand Pharmaceuticals Inc Stock (LGND) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-10 | Iniziato | Stifel | Buy |
| 2024-10-03 | Iniziato | Oppenheimer | Outperform |
| 2024-07-30 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-04-14 | Ripresa | Stephens | Overweight |
| 2021-02-04 | Reiterato | H.C. Wainwright | Buy |
| 2020-10-06 | Iniziato | Barclays | Overweight |
| 2020-03-24 | Downgrade | Argus | Buy → Hold |
| 2020-03-10 | Iniziato | Guggenheim | Neutral |
| 2020-02-06 | Iniziato | The Benchmark Company | Buy |
| 2019-09-19 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2019-06-11 | Iniziato | Barclays | Equal Weight |
| 2019-05-03 | Reiterato | H.C. Wainwright | Buy |
| 2019-03-06 | Reiterato | H.C. Wainwright | Buy |
| 2018-10-29 | Aggiornamento | ROTH Capital | Neutral → Buy |
| 2018-10-02 | Reiterato | H.C. Wainwright | Buy |
| 2018-09-11 | Reiterato | Argus | Buy |
| 2018-08-17 | Iniziato | Goldman | Neutral |
| 2018-08-08 | Downgrade | ROTH Capital | Buy → Neutral |
| 2018-06-21 | Iniziato | Argus | Buy |
| 2017-12-27 | Reiterato | H.C. Wainwright | Buy |
| 2017-09-05 | Ripresa | H.C. Wainwright | Buy |
| 2016-10-05 | Reiterato | H.C. Wainwright | Buy |
| 2016-08-05 | Downgrade | Deutsche Bank | Hold → Sell |
| 2016-03-11 | Iniziato | Sidoti | Buy |
| 2016-03-03 | Iniziato | H.C. Wainwright | Buy |
Mostra tutto
Ligand Pharmaceuticals Inc Borsa (LGND) Ultime notizie
Ligand Pharmaceuticals (NASDAQ:LGND) Price Target Raised to $185.00 - MarketBeat
Ligand Pharmaceuticals shares rise 3.65% intraday after pricing $400 million convertible senior notes offering. - AInvest
Ligand's $400M Convertible Notes Offering: A Strategic Move for M&A-Driven Growth and Shareholder Value - AInvest
Ligand Prices $400 Million Convertible Senior Notes Offering - MarketScreener
Ligand Pharmaceuticals Prices Offering Of $400 Mln Of Senior Notes - Nasdaq
Ligand Pharmaceuticals Experiences Strong Q2 Earnings with Robust Revenue Growth, Successful Mergers and Investments, and Raised Financial Guidance. - AInvest
Analysts Bullish on Insmed and Ligand Pharma: Strong Buy Ratings and High Price Targets - AInvest
Ligand Pharmaceuticals Secures $400M in Convertible Debt Offering - AInvest
Ligand Pharmaceuticals' Convertible Notes Offering: A Strategic Move for Capital Optimization and Growth - AInvest
Ligand Pharmaceuticals prices $400 million convertible notes offering By Investing.com - Investing.com Canada
Ligand's Convertible Notes Offering: Balancing Dilution Risks and Strategic Flexibility in Biopharma Financing - AInvest
Ligand Pharmaceuticals Prices $400 Million Convertible Senior Notes Due 2030 - Quiver Quantitative
Ligand Secures $400M Convertible Note Deal: Key Terms Reveal 0.75% Rate and $15M Share Buyback - Stock Titan
Ligand prices $400 million convertible senior notes offering - MarketScreener
Ligand Announces Pricing of $400 Million Convertible Senior Notes Offering - GlobeNewswire Inc.
Ligand Pharmaceuticals Inc. Reports Strong Q2 Earnings - TipRanks
LGND: Getting In Tune with MedTech - Zacks Small Cap Research
Ligand Pharma Proposes Private Offering Of $400 Mln Of Sr. Notes - Nasdaq
Ligand Pharmaceuticals shares fall 4.06% premarket after announcing a $400 million convertible senior notes offering. - AInvest
Ligand Announces $400M Convertible Senior Notes Offering Due 2030. - AInvest
Ligand Pharmaceuticals plans $400 million convertible notes offering By Investing.com - Investing.com Canada
Ligand Pharmaceuticals to Offer $400mln Convertible Senior Notes Due 2030. - AInvest
Ligand Announces Proposed Offering of $400 Million of Convertible Senior Notes Due 2030 - Stock Titan
Ligand's Q2 2025: Unraveling Contradictions in Pelthos Launch, Deal Strategies, and Market Dynamics - AInvest
Will Ligand Pharmaceuticals Incorporated Recover After Recent DeclineStable Entry High Return Opportunities in Focus - beatles.ru
A Quick Look at Today's Ratings for Ligand Pharmaceuticals(LGND.US), With a Forecast Between $157 to $185 - 富途牛牛
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q2 2025 Earnings Call Transcript - Insider Monkey
Ligand: RBC Raises PT to $185, Maintains Outperform Rating - AInvest
Ligand Pharma stock price target raised to $185 from $155 at RBC Capital - Investing.com Canada
Ligand Pharmaceuticals Among 3 Stocks Possibly Trading Below Intrinsic Value Estimates - Yahoo Finance
Ligand Pharmaceuticals Q2 2025 Earnings Call Highlights: Robust Royalty Growth and Strategic Partnerships - AInvest
Ligand Pharmaceuticals Raises FY25 EPS and Revenue Outlook, Boosts EPS View to $6.70-$7.00 and Revenue View to $200M-$225M. - AInvest
Ligand Pharmaceuticals Reports Q2 EPS and Revenue Above Consensus, Raises 2025 Guidance - AInvest
Ligand Pharmaceuticals Inc (LGND) Q2 2025 Earnings Call Highlights: Robust Royalty Growth and ... By GuruFocus - Investing.com Canada
Ligand Pharmaceuticals Reports Strong Q2 2025 Results - TipRanks
Ligand Pharmaceuticals Q2 2025 Earnings Call Transcript - MarketBeat
Ligand Pharmaceuticals Raises 2025 Revenue Guidance to $225M Amid Royalty Portfolio Momentum - AInvest
Transcript : Ligand Pharmaceuticals Incorporated, Q2 2025 Earnings Call, Aug 07, 2025 - MarketScreener
Ligand Pharma stock price target raised to $167 by Oppenheimer on strong royalty growth - Investing.com Canada
Earnings call transcript: Ligand Pharmaceuticals Q2 2025 beats forecasts, stock rises - Investing.com Canada
Ligand Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Ligand: Q2 Earnings Snapshot - San Francisco Chronicle
Ligand Q2 2025 presentation: 57% royalty growth drives raised guidance By Investing.com - Investing.com Canada
Ligand Pharmaceuticals Q2 2025 Earnings: Revenue Surpasses Estimates at $47.6M, EPS Falls Short at $0.24 - GuruFocus
Ligand Pharmaceuticals Reports 57% Increase in Royalty Revenue and Raises 2025 Financial Guidance - Quiver Quantitative
Ligand Pharmaceuticals Q2 revenue up 15%, raises 2025 guidance - MarketScreener
Ligand Q2 revenue up 57% YoY, FY23 guidance raised to $200-$225 mln. - AInvest
Ligand Reports Second Quarter 2025 Financial Results and Raises Guidance - GlobeNewswire
Ligand Pharmaceuticals Reports Q2 2025 Financial Results - TradingView
Press Release: Ligand Reports Second Quarter 2025 Financial Results and Raises Guidance - 富途牛牛
Investors in Ligand Pharmaceuticals (NASDAQ:LGND) Have Seen Notable Returns of 36% Over the Past Year - 富途牛牛
Ligand Pharmaceuticals Inc Azioni (LGND) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.91%
3.06%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):